Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [6141]

WCC 2024: Eliminating 5% of all cancers globally could be a reality with today's announcement calling for global gender-neutral HPV vaccination by 2030

WCC 2024: Eliminating 5% of all cancers globally could be a reality with today's announcement calling for global...

WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous amivantamab-vmjw

WCLC 2024: Dexamethasone reduces infusion-related reactions in patients with EGFR-mutated non-small cell lung...

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma

FDA approves pembrolizumab with chemotherapy for unresectable advanced or metastatic malignant pleural mesothelioma

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection

Researcher develops drug delivery system for chemo-induced hearing loss

Researcher develops drug delivery system for chemo-induced hearing loss

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

Tumor-induced B cell changes reveal potential biomarker for treatment response in triple negative breast cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in patients with ROS1+ non-small cell lung cancer

WCLC 2024: Phase II study of taletrectinib shows clinically meaningful overall response and favorable safety in...

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated advanced non-squamous NSCLC

WCLC 2024: Results from CARMEN-LC03 phase 3 study of tusamitamab ravtansine vs. docetaxel in previously treated...

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met protein-overexpressing EGFR WT nonsquamous NSCLC

WCLC 2024: LUMINOSITY trial demonstrates telisotuzumab vedotin shows durable response in Asian patients with c-Met...

University develops novel bone cancer therapy which has 99% success rate

University develops novel bone cancer therapy which has 99% success rate

More from ecancer